The Mechanism of Endogenous Nociceptin/Orphanin FQ(N/OFQ) and β1-adrenoceptor Autoantibody in Promoting Ischemic Arrhythmia in Rats
Launched by SECOND HOSPITAL OF SHANXI MEDICAL UNIVERSITY · Apr 25, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain substances in the body, specifically nociceptin/orphanin FQ (N/OFQ) and autoantibodies against β1-adrenoceptors (β1-AA), may influence abnormal heart rhythms (arrhythmias) that can occur during heart conditions like acute myocardial ischemia (a situation where the heart doesn’t get enough blood). Researchers are looking to understand how N/OFQ affects the behavior of β1-AR (a type of receptor in the heart) and its connection to arrhythmias. This knowledge could help in developing new treatments for patients experiencing these heart issues.
To participate, individuals should be between 65 and 104 years old and have a diagnosis of type 2 diabetes or coronary heart disease, as defined by specific health guidelines. However, those with heart failure, certain cancers, immune diseases, or diabetes (for coronary heart disease patients) cannot join. Participants will help researchers by providing blood samples to explore the relationship between N/OFQ and β1-AA. The trial is not yet recruiting, so interested individuals will need to wait for further announcements about how to get involved.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:1) Inclusion criteria for patients with diabetes: refer to the diagnostic criteria for type 2 diabetes (T2DM) in the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2017) 2) Inclusion criteria for patients with coronary heart disease: patients with clinically diagnosed coronary heart disease according to the 1979 WHO Diagnostic Criteria for Ischemic Heart Disease, and exclusion criteria include heart failure, tumor, immune disease and diabetes. -
- • Exclusion Criteria:Exclusion criteria for patients with coronary heart disease: including heart failure, tumor, immune disease and diabetes. -
About Second Hospital Of Shanxi Medical University
The Second Hospital of Shanxi Medical University is a prominent clinical research institution dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. As a key affiliate of Shanxi Medical University, the hospital combines cutting-edge research with clinical expertise, facilitating a multidisciplinary approach to address various health challenges. Committed to ethical research practices and patient safety, the Second Hospital actively collaborates with healthcare professionals and academic partners to conduct rigorous studies that contribute to evidence-based medicine and enhance treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
yi Han
Study Director
Second Hospital of Shanxi Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported